Denali Therapeutics (DNLI) Stock Forecast, Price & News

Denali Therapeutics (NASDAQ:DNLI) Frequently Asked Questions

Is Denali Therapeutics a buy right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Denali Therapeutics in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Denali Therapeutics stock.
View analyst ratings for Denali Therapeutics or view top-rated stocks.

When is Denali Therapeutics' next earnings date?

Denali Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022.
View our earnings forecast for Denali Therapeutics.

How were Denali Therapeutics' earnings last quarter?

Denali Therapeutics Inc. (NASDAQ:DNLI) released its quarterly earnings results on Thursday, May, 5th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.47) by $0.06. The company had revenue of $42.10 million for the quarter, compared to analysts' expectations of $33.32 million. Denali Therapeutics had a negative trailing twelve-month return on equity of 28.83% and a negative net margin of 344.79%. The business's quarterly revenue was up 432.9% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.58) EPS.
View Denali Therapeutics' earnings history.

What price target have analysts set for DNLI?

7 brokerages have issued 1-year price objectives for Denali Therapeutics' stock. Their forecasts range from $48.00 to $111.00. On average, they anticipate Denali Therapeutics' share price to reach $88.00 in the next year. This suggests a possible upside of 256.0% from the stock's current price.
View analysts' price targets for Denali Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Denali Therapeutics' key executives?

Denali Therapeutics' management team includes the following people:

• Dr. Ryan J. Watts Ph.D., Co-Founder, Pres, CEO & Director (Age 46, Pay $1.13M)
• Dr. Alexander O. Schuth M.D., Co-Founder, COO & Sec. (Age 49, Pay $755.81k) (LinkedIn Profile)
• Dr. Marc Tessier-Lavigne Ph.D., Co-Founder, Chairman of Scientific Advisory Board & Independent Director (Age 62, Pay $58.14k)
• Mr. Steve Edward Krognes, CFO & Treasurer (Age 54, Pay $813.44k)
• Dr. Carole Ho M.D., Chief Medical Officer & Head of Devel. (Age 49, Pay $769.39k)
• Mr. Tyler M. Nielsen, VP of Corp. Fin. (Age 44)
• Dr. Dana Andersen, Chief Technical and Manufacturing Officer
• Mr. Joe Lewcock, Chief Scientific Officer
• Dr. Laura Hansen, VP of Investor Relations
• Mr. Chris Walsh, Associate Gen. Counsel

What is Ryan Watts' approval rating as Denali Therapeutics' CEO?

1 employees have rated Denali Therapeutics CEO Ryan Watts on Glassdoor.com. Ryan Watts has an approval rating of 100% among Denali Therapeutics' employees. This puts Ryan Watts in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Denali Therapeutics' key competitors?

Some companies that are related to Denali Therapeutics include Qiagen (QGEN), Qiagen (QGEN), Repligen (RGEN), Neurocrine Biosciences (NBIX), Halozyme Therapeutics (HALO), Exelixis (EXEL), Ginkgo Bioworks (DNA), Novavax (NVAX), CRISPR Therapeutics (CRSP), Ablynx (ABLYF), Abcam (ABCM), Vir Biotechnology (VIR), Iovance Biotherapeutics (IOVA), Beam Therapeutics (BEAM) and Bavarian Nordic A/S (BVNRY).
View all of DNLI's competitors.

What other stocks do shareholders of Denali Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Denali Therapeutics investors own include Progenics Pharmaceuticals (PGNX), Editas Medicine (EDIT), Intellia Therapeutics (NTLA), Sangamo Therapeutics (SGMO), Kratos Defense & Security Solutions (KTOS), CRISPR Therapeutics (CRSP), Anavex Life Sciences (AVXL), NVIDIA (NVDA), Invitae (NVTA) and Pretium Resources (PVG).

When did Denali Therapeutics IPO?

(DNLI) raised $149 million in an initial public offering (IPO) on Friday, December 8th 2017. The company issued 8,300,000 shares at a price of $17.00-$19.00 per share. Goldman Sachs, Morgan Stanley and J.P. Morgan served as the underwriters for the IPO and Evercore ISI was co-manager.

What is Denali Therapeutics' stock symbol?

Denali Therapeutics trades on the NASDAQ under the ticker symbol "DNLI."

Who are Denali Therapeutics' major shareholders?

Denali Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (12.19%), BlackRock Inc. (6.66%), Vanguard Group Inc. (6.60%), State Street Corp (3.11%), Gilder Gagnon Howe & Co. LLC (2.13%) and Bank of New York Mellon Corp (1.31%). Company insiders that own Denali Therapeutics stock include Alexander O Schuth, Alexander O Schuth, Carole Ho, David P Schenkein, Douglas K Bratton, Marc Tessier-Lavigne, Ryan J Watts, Ryan J Watts, Steve E Krognes, Steve E Krognes, Vicki L Sato and Vicki L Sato.
View institutional ownership trends for Denali Therapeutics.

Which institutional investors are selling Denali Therapeutics stock?

DNLI stock was sold by a variety of institutional investors in the last quarter, including Gilder Gagnon Howe & Co. LLC, Prudential Financial Inc., Citigroup Inc., Baillie Gifford & Co., Integral Health Asset Management LLC, AIA Group Ltd, Principal Financial Group Inc., and UBS Group AG. Company insiders that have sold Denali Therapeutics company stock in the last year include Alexander O Schuth, Carole Ho, Marc Tessier-Lavigne, Ryan J Watts, Steve E Krognes, and Vicki L Sato.
View insider buying and selling activity for Denali Therapeutics or view top insider-selling stocks.

Which institutional investors are buying Denali Therapeutics stock?

DNLI stock was acquired by a variety of institutional investors in the last quarter, including State Street Corp, Bank of New York Mellon Corp, Woodline Partners LP, Federated Hermes Inc., Dimensional Fund Advisors LP, BlackRock Inc., The Manufacturers Life Insurance Company , and Renaissance Technologies LLC.
View insider buying and selling activity for Denali Therapeutics or or view top insider-buying stocks.

How do I buy shares of Denali Therapeutics?

Shares of DNLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Denali Therapeutics' stock price today?

One share of DNLI stock can currently be purchased for approximately $24.72.

How much money does Denali Therapeutics make?

Denali Therapeutics has a market capitalization of $3.04 billion and generates $48.66 million in revenue each year. The company earns $-290.58 million in net income (profit) each year or ($2.34) on an earnings per share basis.

How many employees does Denali Therapeutics have?

Denali Therapeutics employs 380 workers across the globe.

What is Denali Therapeutics' official website?

The official website for Denali Therapeutics is www.denalitherapeutics.com.

How can I contact Denali Therapeutics?

Denali Therapeutics' mailing address is 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at (615) 866-8548 or via email at [email protected].